IGF-1 LR3 Research Overview (also known as Long R3 IGF-1)
A long-acting synthetic analog of Insulin-Like Growth Factor 1 (IGF-1), modified to resist binding to IGF-binding proteins, extending its active half-life and systemic distribution compared to native IGF-1. Studied for anabolic effects on muscle and bone, recovery enhancement, and IGF-1 receptor-mediated signaling.
What Is IGF-1 LR3?
IGF-1 LR3 (Insulin-like Growth Factor 1 Long R3) is a synthetic analog of IGF-1 modified with an Arg-Gly-Glu (R3) substitution at position 3 and an N-terminal 13-amino-acid extension. These modifications dramatically reduce its binding affinity for IGF binding proteins (IGFBPs) — the serum proteins that normally sequester approximately 97% of IGF-1, limiting its biological activity.
Extended Activity Profile
Native IGF-1 has a half-life of approximately 10 minutes when free (not IGFBP-bound). IGF-1 LR3's reduced IGFBP affinity extends its active half-life to approximately 20–30 hours, allowing it to maintain prolonged IGF-1 receptor activation throughout the body — a research property not achievable with native IGF-1 without continuous infusion.
Muscle Research and Safety
IGF-1 receptor activation in skeletal muscle activates the PI3K/Akt/mTOR pathway (promoting protein synthesis) and stimulates satellite cell proliferation and differentiation (enabling muscle repair and growth). Because IGF-1 signaling promotes cell growth broadly, prolonged or excessive use carries potential for off-target tissue growth effects. It is a research compound only and not approved for clinical use.
Quick Reference
| Literature-Reported Dose Range | 20-40mcg for beginners |
| Literature-Reported Frequency | Once daily post-workout |
| Literature-Reported Cycle Length | 4-6 weeks maximum |
| Literature-Reported Washout | Equal or longer off-cycle (4-6+ weeks) for receptor recovery |
| Storage | Lyophilized: -20°C long-term. Reconstituted in acetic acid: 2-8°C up to 1 year. In bac water: 7 days max. |
| Sites Reported in Studies | SubQ: Lower abdomen, outer thigh, upper arm. Rotate sites daily. |
| Timing | Within 15-30 minutes post-workout with immediate carbohydrate intake |
Research Indications
Muscle Growth
Muscle Hypertrophy
Animal studies show 15-20% lean mass gains in 4 weeks through satellite cell activation and protein synthesis enhancement. No human data exists.
Anti-Catabolic Effects
Preserves lean mass in cachexia models through ubiquitin-proteasome inhibition. Cancer cachexia rats maintained 30% more muscle versus placebo.
Hyperplasia Induction
Unique ability to create new muscle fibers via satellite cell differentiation, not just enlarging existing fibers. Permanent structural changes possible.
Tissue Repair
Wound Healing Acceleration
Promotes keratinocyte migration, epithelialization, and collagen synthesis. Mouse studies show faster wound closure and reduced scarring.
Ligament/Tendon Recovery
Rat MCL injury model showed improved maximum force and stress with enhanced type-I collagen expression. May overcome mechanical unloading effects.
Burn Recovery
Children with severe burns treated with native IGF-1 showed protein-sparing effects. LR3 variant untested in humans but theoretically more potent.
Metabolic
Nutrient Partitioning
Directs calories toward muscle rather than fat storage. Inhibits glucose uptake in adipocytes while promoting muscle uptake.
Fat Loss Enhancement
Promotes lipolysis and fatty acid oxidation independent of caloric deficit. Particularly targets visceral adipose tissue in animal models.
Insulin Sensitivity (Acute)
Short-term use may improve glucose uptake, though chronic exposure causes paradoxical insulin resistance through receptor downregulation.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Research Beginner Protocol | 20-30mcg | Once daily, post-workout | SubQ |
| Intermediate Research Use | 40-60mcg | Once daily, post-workout or morning | SubQ or IM |
| Advanced Research Protocol | 80-100mcg | Once daily or split AM/PM | SubQ or site-specific IM |
| Women's Research Protocol | 10-20mcg | Once daily | SubQ only |
Timing
Within 15-30 minutes post-workout with immediate carbohydrate intake. Typical onset: initial: 1-2 weeks. Notable: 2-4 weeks. Desensitization: 6 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
CRITICAL: Both activate GLUT4 translocation and drive glucose into cells independently. Combining exogenous insulin with IGF-1 LR3 can cause severe, life-threatening hypoglycemia. Never co-administer — if insulin is used in a protocol, carefully time IGF-1 LR3 injections at least 4–6 hours apart and monitor blood glucose closely.
Creates excessive IGF-1 levels. HGH already elevates endogenous IGF-1, adding exogenous LR3 amplifies cancer risk and organ hypertrophy.
Both stimulate GH/IGF-1 axis. Combined use may cause receptor desensitization and compounded metabolic effects.
MK-677 increases endogenous IGF-1. Monitor for joint pain, water retention, and insulin sensitivity disruption.
Synergistic hypoglycemic effects can be life-threatening. Requires professional medical supervision if combined.
Popular healing stack. BPC-157 (250-500mcg 2x daily) with IGF-1 LR3 (40-60mcg daily) may accelerate tissue repair.
Complementary healing mechanisms. TB-500 (2-5mg weekly) with IGF-1 LR3 enhances recovery through different pathways.
Amplified anabolic effects but substantially increased health risks including organ hypertrophy and metabolic dysfunction.
May help mitigate insulin resistance from chronic IGF-1 use, but requires blood glucose monitoring and dose adjustment.
Both affect growth factor pathways and neuroplasticity. IGF-1 LR3 binds IGF-1 receptors while Cerebrolysin enhances BDNF/NGF. Potential for additive neurotrophic effects - use conservative doses and monitor for signs of excessive stimulation.
Reported Research Timeline
01Week 1–2 (reported in cited studies): increased pump, fullness, possible hypoglycemia episodes if carbs inadequate
02Week 2–4 (reported in cited studies): enhanced recovery, strength gains, visible muscle fullness, possible water retention
03Week 4–6 (reported in cited studies): maximum effects but approaching receptor desensitization. Joint stiffness common.
04Post-cycle: Gradual loss of pumps over 1-2 weeks. Strength/size gains may persist if training maintained.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
CRITICAL: Consume 30-60g fast carbohydrates immediately after injection
Never inject before sleep - overnight hypoglycemia risk
Monitor blood glucose regularly, especially first week
Not Recommended with any cancer history or undiagnosed growths
May cause organ hypertrophy (heart, intestines) with prolonged use
WADA prohibited - will cause failed drug test in athletes
Seek Medical Attention If:
Severe or recurring hypoglycemia despite carbohydrate intake
Unusual growths, lumps, or rapid mole changes
Severe joint pain or carpal tunnel symptoms
Persistent nausea, headaches, or vision changes
Signs of organ enlargement (abdominal distension)
Extreme fatigue or mental fog
Quality Indicators
Acceptable Range
Research Chemical Status
Never approved for human use. Zero human clinical trials. All use represents uncontrolled experimentation.
Quality Concern
Severe Hypoglycemia Risk
Can cause life-threatening low blood sugar lasting 20-30 hours. Multiple animal deaths documented in studies.
Quality Concern
Cancer Proliferation Concern
UK Biobank study links elevated IGF-1 to multiple cancers. May accelerate growth of existing tumors.
Verified Marker
Purity Testing Essential
Require HPLC >95% and mass spectrometry confirmation. Black market samples often degraded or contaminated.
Acceptable Range
Species-Specific Responses
Works in rats, fails in guinea pigs, inhibits growth in pigs. Human response entirely unknown.
Verified Marker
Proper Cold Storage Required
Lyophilized powder stable at -20°C. Ships at room temperature but refrigerate immediately upon arrival.
Research Citations
- Rat Muscle Hypertrophy Study (Florini et al.)
Sprague-Dawley Rats | 2.5mg/kg/day | 4 weeks | 15-20% lean mass increase - Fetal Sheep Metabolic Study (Children's Hospital Colorado)
Fetal Sheep | 6.6μg/kg/h acute, 1.17μg/kg/h chronic | 90 min to 1 week | Study halted early - Pig Growth Inhibition Study
Domestic Pigs | 180μg/kg/day | 4 days | Paradoxical growth reduction - Guinea Pig Organ Study
Guinea Pigs | 120μg/day | 7 days | No overall growth, organ-specific effects - Cancer Cachexia Rat Model
Tumor-bearing Rats | 0.3mg/kg/day | 14 days | 30% lean mass preservation - Alzheimer's Mouse Model (5XFAD)
Transgenic Mice | Intranasal LR3 | 7 months | Plaque remodeling without cognitive improvement - Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel MG, Narayan S, Cui MH, 2025, J Alzheimers Dis - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)
Research Focus
Muscle hypertrophy, Satellite cell activation, Fat loss, Tissue growth, Insulin-like signaling
Verified Vendors Carrying IGF-1 LR3
Frequently Asked Questions
What should researchers watch for with IGF-1 LR3?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with IGF-1 LR3?
Week 1–2 (reported in cited studies): increased pump, fullness, possible hypoglycemia episodes if carbs inadequate
How is IGF-1 LR3 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →